Free tool
FAERS Monitor: Salagen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020237 or its brand name (Salagen, Pilocarpine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,485
Serious
1,537
62% of reports
Hospitalization
686
Death reported
101
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective223
- headache199
- pain195
- fatigue187
- nausea174
- off label use154
- dyspnoea149
- arthralgia141
- dizziness130
- fall127
- diarrhoea124
- cough117
- malaise105
- weight increased101
- eye pain100
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 60 |
| 2005 | 62 |
| 2006 | 38 |
| 2007 | 34 |
| 2008 | 51 |
| 2009 | 73 |
| 2010 | 88 |
| 2011 | 55 |
| 2012 | 68 |
| 2013 | 77 |
| 2014 | 77 |
| 2015 | 100 |
| 2016 | 105 |
| 2017 | 123 |
| 2018 | 112 |
| 2019 | 141 |
| 2020 | 167 |
| 2021 | 140 |
| 2022 | 176 |
| 2023 | 160 |
| 2024 | 178 |
| 2025 | 228 |
| 2026 | 172 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,674 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye painSignal | 100 | 15.0 | 12.4 | 1,297 |
| weight increasedSignal | 101 | 3.8 | 3.2 | 209 |
| coughSignal | 117 | 3.5 | 3.0 | 213 |
| fallSignal | 127 | 3.2 | 2.7 | 196 |
| arthralgiaSignal | 141 | 2.9 | 2.4 | 173 |
| painSignal | 195 | 2.7 | 2.3 | 211 |
| headacheSignal | 199 | 2.7 | 2.4 | 215 |
| dyspnoeaSignal | 149 | 2.2 | 1.9 | 102 |
| dizzinessSignal | 130 | 2.2 | 1.9 | 87 |
| fatigueSignal | 187 | 2.0 | 1.8 | 101 |
| malaiseSignal | 105 | 2.0 | 1.7 | 55 |
| nausea | 174 | 1.9 | 1.6 | 71 |
| diarrhoea | 124 | 1.6 | 1.4 | 30 |
| off label use | 154 | 1.5 | 1.3 | 25 |
| drug ineffective | 223 | 1.4 | 1.3 | 31 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.